PL1629091T3 - Kompozycja zawierająca poliproteinę ns3/ns4 i polipeptyd ns5b hcv, wektory ekspresyjne obejmujące odpowiadające im sekwencje kwasów nukleinowych i ich zastosowanie terapeutyczne - Google Patents

Kompozycja zawierająca poliproteinę ns3/ns4 i polipeptyd ns5b hcv, wektory ekspresyjne obejmujące odpowiadające im sekwencje kwasów nukleinowych i ich zastosowanie terapeutyczne

Info

Publication number: PL1629091T3
Authority: PL; Poland
Prior art keywords: expressed; hcv; virus; ns5b; polyprotein
Prior art date: 2003-06-05

Application number

PL04742880T

Other languages

English (en)

Inventor

Anne Fournillier

Geneviève Inchauspe

Jean-Daniel Abraham

Maria Dimitrova-Tchomakov

Marie Parnot

Original Assignee

Transgene Sa

Inst Nat Sante Rech Med

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-05

Filing date

2004-06-04

Publication date

2011-10-31

2004-06-04 Application filed by Transgene Sa, Inst Nat Sante Rech Med filed Critical Transgene Sa

2011-10-31 Publication of PL1629091T3 publication Critical patent/PL1629091T3/pl

Links

239000013604 expression vector Substances 0.000 title abstract 6
108010076039 Polyproteins Proteins 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
229920001184 polypeptide Polymers 0.000 title abstract 2
102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
101710112514 Host translation inhibitor 5b Proteins 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1
241000711549 Hepacivirus C Species 0.000 abstract 4
241000700605 Viruses Species 0.000 abstract 3
241001465754 Metazoa Species 0.000 abstract 2
238000006386 neutralization reaction Methods 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
102000004169 proteins and genes Human genes 0.000 abstract 2
229960005486 vaccine Drugs 0.000 abstract 2
241000699670 Mus sp. Species 0.000 abstract 1
241000700618 Vaccinia virus Species 0.000 abstract 1
206010046865 Vaccinia virus infection Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000000284 extract Substances 0.000 abstract 1
230000001553 hepatotropic effect Effects 0.000 abstract 1
230000003053 immunization Effects 0.000 abstract 1
238000002649 immunization Methods 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
244000005700 microbiome Species 0.000 abstract 1
230000002611 ovarian Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
238000002962 plaque-reduction assay Methods 0.000 abstract 1
241000701161 unidentified adenovirus Species 0.000 abstract 1
208000007089 vaccinia Diseases 0.000 abstract 1
239000012873 virucide Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PL04742880T 2003-06-05 2004-06-04 Kompozycja zawierająca poliproteinę ns3/ns4 i polipeptyd ns5b hcv, wektory ekspresyjne obejmujące odpowiadające im sekwencje kwasów nukleinowych i ich zastosowanie terapeutyczne PL1629091T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR0306772A FR2855758B1 (fr)	2003-06-05	2003-06-05	Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
EP04742880A EP1629091B1 (fr)	2003-06-05	2004-06-04	Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
PCT/FR2004/050214 WO2004111082A2 (fr)	2003-06-05	2004-06-04	Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique

Publications (1)

Publication Number	Publication Date
PL1629091T3 true PL1629091T3 (pl)	2011-10-31

Family

ID=33443147

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04742880T PL1629091T3 (pl)	2003-06-05	2004-06-04	Kompozycja zawierająca poliproteinę ns3/ns4 i polipeptyd ns5b hcv, wektory ekspresyjne obejmujące odpowiadające im sekwencje kwasów nukleinowych i ich zastosowanie terapeutyczne

Country Status (20)

Country	Link
US (3)	US20060134065A1 (pl)
EP (1)	EP1629091B1 (pl)
JP (1)	JP4625803B2 (pl)
KR (1)	KR101158741B1 (pl)
CN (1)	CN100506980C (pl)
AT (1)	ATE508184T1 (pl)
AU (1)	AU2004247457B2 (pl)
BR (1)	BRPI0411011A (pl)
CA (1)	CA2528240C (pl)
CY (1)	CY1112081T1 (pl)
DE (1)	DE602004032536D1 (pl)
DK (1)	DK1629091T3 (pl)
ES (1)	ES2362578T3 (pl)
FR (1)	FR2855758B1 (pl)
MX (1)	MXPA05013127A (pl)
PL (1)	PL1629091T3 (pl)
PT (1)	PT1629091E (pl)
SI (1)	SI1629091T1 (pl)
WO (1)	WO2004111082A2 (pl)
ZA (1)	ZA200509937B (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6501990B1 (en)	1999-12-23	2002-12-31	Cardiac Pacemakers, Inc.	Extendable and retractable lead having a snap-fit terminal connector
US7695960B2 (en) *	2003-06-05	2010-04-13	Transgene S.A.	Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use
US20080249283A1 (en) *	2004-04-30	2008-10-09	Tomoya Miyakawa	Hla-Binding Peptides, Precursors Thereof, Dna Fragments and Recombinant Vectors that Code for Those Peptide Sequences
ES2291071B1 (es) *	2005-06-13	2009-03-16	Proyecto De Biomedicina Cima, S.L.	Agentes y metodos basados en el uso del dominio eda de la fibronectina.
EP1993603B1 (en) *	2006-03-09	2012-05-02	Transgene SA	Hepatitis c virus non structural fusion protein
US8914725B2 (en)	2007-04-11	2014-12-16	Gvbb Holdings S.A.R.L.	Method and apparatus for enhancing digital video effects (DVE)
WO2009079834A1 (en) *	2007-12-18	2009-07-02	Peking University People's Hospital	An anti-hcv vaccine and preparation methods and uses thereof
JP5584407B2 (ja) *	2008-03-07	2014-09-03	公益財団法人東京都医学総合研究所	Ｃ型肝炎ウイルス遺伝子を有する組換えワクシニアウイルス
PT2382474E (pt)	2009-01-20	2015-06-03	Transgene Sa	Icam-1 solúvel como biomarcador para a previsão de uma resposta terapêutica
BRPI1009892A2 (pt)	2009-03-24	2016-03-15	Transgène S A	método ex-vivo para avaliar a eficácia de um tratamento em um paciente, e, kit para testar se um paciente está respondendo terapeuticamente a um método de tratamento compreendendo administração de uma composição imunogênica
SG176554A1 (en)	2009-05-12	2012-01-30	Transgene Sa	Method for orthopoxvirus production and purification
EP2452194B1 (en)	2009-07-10	2015-11-11	Transgene SA	Biomarker for selecting patients and related methods
AU2010275764A1 (en)	2009-07-21	2012-03-15	Transgene Sa	Enzymatic composition for the digestion of chicken embryos
CA2770075C (en) *	2009-08-07	2021-08-24	Perrine Martin	Composition for treating hbv infection
WO2011073741A1 (en)	2009-12-18	2011-06-23	Transgene Sa	A method and a system for automatically processing multiple measurements of biological quantifiable parameters
DK3205353T3 (da) *	2011-03-21	2021-04-06	Altimmune Inc	Hurtig- og langtidsvirkende immunologisk terapeutisk middel
TW201318637A (zh)	2011-09-29	2013-05-16	Transgene Sa	免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（一）
WO2013045668A2 (en)	2011-09-29	2013-04-04	Transgene Sa	Immunotherapy composition and regimen for treating hepatitis c virus infection
WO2014009433A1 (en)	2012-07-10	2014-01-16	Transgene Sa	Mycobacterium resuscitation promoting factor for use as adjuvant
TWI690322B (zh)	2012-10-02	2020-04-11	法商傳斯堅公司	含病毒的調配物及其使用
WO2014064534A2 (en)	2012-10-05	2014-05-01	Chrontech Pharma Ab	Injection needle, device, immunogenic compositions and method of use
US10517943B2 (en)	2014-12-01	2019-12-31	Transgene S.A.	Stable liquid vaccinia virus formulations
CA2975432A1 (en)	2015-02-13	2016-08-18	Transgene Sa	Immunotherapeutic vaccine and antibody combination therapy
CA3023022A1 (en)	2016-05-04	2017-11-09	Transgene Sa	Combination therapy with cpg tlr9 ligand
WO2018069316A2 (en)	2016-10-10	2018-04-19	Transgene Sa	Immunotherapeutic product and mdsc modulator combination therapy
CA3062549A1 (en)	2017-05-15	2018-11-22	Janssen Vaccines & Prevention B.V.	Stable virus-containing composition
EP3624851A1 (en)	2017-05-15	2020-03-25	Janssen Vaccines & Prevention B.V.	Stable virus-containing composition
EP3847246A1 (en)	2018-09-06	2021-07-14	Bavarian Nordic A/S	Storage improved poxvirus compositions
JP7712284B2 (ja)	2020-03-12	2025-07-23	バヴァリアン・ノルディック・アクティーゼルスカブ	ポックスウイルスの安定性を改善する組成物
CN117379542A (zh) *	2023-09-27	2024-01-12	广州佰芮慷生物科技有限公司	一种用于预防多基因型丙型肝炎病毒的腺病毒载体疫苗

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5712087A (en) *	1990-04-04	1998-01-27	Chiron Corporation	Immunoassays for anti-HCV antibodies employing combinations of hepatitis C virus (HCV) antigens
EP1056762A4 (en)	1998-01-30	2003-07-23	Gen Hospital Corp	GENETIC IMMUNIZATION WITH HEPATITIS C VIRUS NON-STRUCTURAL PROTEINS
US7052696B2 (en) *	1998-07-10	2006-05-30	The United States Of America As Represented By The Department Of Health And Human Services	Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
CN1147346C (zh) *	1999-07-12	2004-04-28	赛斯纯净气体公司	具有氢气吸附和过滤集成式装置的气体净化系统
ES2411096T3 (es) *	1999-10-27	2013-07-04	Novartis Vaccines And Diagnostics, Inc.	Activación de linfocitos T específicos contra el VHC
US6986892B1 (en) *	1999-11-24	2006-01-17	Chiron Corporation	Immunogenic Hepatitis C virus non-structural polypeptides
FR2839722A1 (fr) *	2002-05-17	2003-11-21	Bio Merieux	Nouvelles compositions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c
US7695960B2 (en) *	2003-06-05	2010-04-13	Transgene S.A.	Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use

2003
- 2003-06-05 FR FR0306772A patent/FR2855758B1/fr not_active Expired - Fee Related
2004
- 2004-06-04 BR BRPI0411011-0A patent/BRPI0411011A/pt not_active IP Right Cessation
- 2004-06-04 PL PL04742880T patent/PL1629091T3/pl unknown
- 2004-06-04 ES ES04742880T patent/ES2362578T3/es not_active Expired - Lifetime
- 2004-06-04 EP EP04742880A patent/EP1629091B1/fr not_active Expired - Lifetime
- 2004-06-04 KR KR1020057023382A patent/KR101158741B1/ko not_active Expired - Fee Related
- 2004-06-04 ZA ZA200509937A patent/ZA200509937B/en unknown
- 2004-06-04 CN CNB2004800222196A patent/CN100506980C/zh not_active Expired - Fee Related
- 2004-06-04 AT AT04742880T patent/ATE508184T1/de active
- 2004-06-04 WO PCT/FR2004/050214 patent/WO2004111082A2/fr not_active Ceased
- 2004-06-04 MX MXPA05013127A patent/MXPA05013127A/es active IP Right Grant
- 2004-06-04 US US10/559,431 patent/US20060134065A1/en not_active Abandoned
- 2004-06-04 AU AU2004247457A patent/AU2004247457B2/en not_active Ceased
- 2004-06-04 JP JP2006508364A patent/JP4625803B2/ja not_active Expired - Fee Related
- 2004-06-04 DE DE602004032536T patent/DE602004032536D1/de not_active Expired - Lifetime
- 2004-06-04 SI SI200431674T patent/SI1629091T1/sl unknown
- 2004-06-04 CA CA2528240A patent/CA2528240C/fr not_active Expired - Fee Related
- 2004-06-04 DK DK04742880.0T patent/DK1629091T3/da active
- 2004-06-04 PT PT04742880T patent/PT1629091E/pt unknown
2009
- 2009-05-26 US US12/472,330 patent/US8057162B2/en not_active Expired - Fee Related
2011
- 2011-07-20 CY CY20111100707T patent/CY1112081T1/el unknown
- 2011-09-23 US US13/241,578 patent/US8541004B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US8057162B2 (en)	2011-11-15
WO2004111082A3 (fr)	2005-02-17
ATE508184T1 (de)	2011-05-15
CA2528240A1 (fr)	2004-12-23
JP4625803B2 (ja)	2011-02-02
KR101158741B1 (ko)	2012-06-22
CN100506980C (zh)	2009-07-01
FR2855758A1 (fr)	2004-12-10
HK1092498A1 (en)	2007-02-09
US20120039938A1 (en)	2012-02-16
ES2362578T3 (es)	2011-07-07
KR20060030476A (ko)	2006-04-10
CA2528240C (fr)	2013-03-05
US8541004B2 (en)	2013-09-24
SI1629091T1 (sl)	2011-07-29
FR2855758B1 (fr)	2005-07-22
AU2004247457A1 (en)	2004-12-23
PT1629091E (pt)	2011-07-28
BRPI0411011A (pt)	2006-07-04
CN1833022A (zh)	2006-09-13
CY1112081T1 (el)	2015-11-04
DE602004032536D1 (de)	2011-06-16
EP1629091A2 (fr)	2006-03-01
AU2004247457B2 (en)	2009-02-05
ZA200509937B (en)	2007-03-28
JP2007527207A (ja)	2007-09-27
DK1629091T3 (da)	2011-08-08
MXPA05013127A (es)	2006-05-25
US20060134065A1 (en)	2006-06-22
US20100008941A1 (en)	2010-01-14
EP1629091B1 (fr)	2011-05-04
WO2004111082A2 (fr)	2004-12-23

Publication	Publication Date	Title
PT1629091E (pt)	2011-07-28	Composição compreendendo a poliproteína ns3/ns4 e o polipéptido ns5b do vhc, vectores de expressão incluindo as sequências nucleicas correspondentes e a sua utilização em terapêutica
Zein et al.	1996	Hepatitis C genotypes: current trends and future implications
Branch et al.	2005	The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others
Weiner et al.	2001	Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity
DK1043399T5 (da)	2004-01-05	Hepatitis C virus cellekultursystem
WO2009014216A1 (ja)	2009-01-29	Ｃ型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体およびその用途
PL1801209T3 (pl)	2011-07-29	Zmodyfikowany genomowy RNA ludzkiego wirusa zapalenia wątroby typu C posiadający zdolność replikacji autonomicznej
JP2008516610A5 (pl)	2008-12-04
Luo	1999	Cellular proteins bind to the poly (U) tract of the 3′ untranslated region of hepatitis C virus RNA genome
Plagemann	1991	Hepatitis C virus
Shimotohno	1995	Hepatitis C virus as a causative agent of hepatocellular carcinoma
AU2001290178A1 (en)	2002-02-25	A hepatitis c virus non-structural ns3/4a fusion gene
Varshney et al.	2012	A review on an update of NS5B polymerase hepatitis C virus inhibitors
Lazdina et al.	2001	Humoral and CD4+ T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes Th1-like responses more effectively as a DNA-based immunogen than as a recombinant protein
WO2006131936B1 (en)	2007-05-31	Hepatitis c virus vaccine
Matsuura et al.	1994	Characterization of HCV structural proteins expressed in various animal cells
DK1417233T3 (da)	2009-06-29	Humant rekombinant antistof mod det hepatitis C (HCV) ikke-strukturelle NS3-protein, nukleinsyre og anvendelser deraf
Thomson et al.	2000	I Molecular biology of hepatitis C virus
Kim et al.	2007	Hepatitis C virus NS2 protein activates cellular cyclic AMP-dependent pathways
Kang et al.	2008	Monoclonal antibody recognizing N‐terminal epitope of hepatitis C virus nonstructural 5B inhibits viral RNA replication
Sbardellati et al.	1999	Identification of a novel sequence at the 3′ end of the GB virus B genome
WO2025075887A3 (en)	2025-05-15	Compositions and methods for preventing or treating hepatitis c viral infections
US20020160936A1 (en)	2002-10-31	Hcv e2 protein binding agents for treatment of hepatitis c virus infection
Kumar et al.	2000	Sequence, expression and reconstitution of an HCV genome from a British isolate derived from a single blood donation
Zhang et al.	1995	Proteolytic processing of the polyprotein of a newly discovered human RNA virus associated with hepatitis